Silver Oak Securities Incorporated Trims Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Silver Oak Securities Incorporated has reduced its stake in Intuitive Surgical, Inc. by 47.1%, now holding 1,110 shares valued at $603,000.
• Several institutional investors have significantly increased their positions in Intuitive Surgical, with Chilton Capital Management LLC raising its stake by 614.3% during the first quarter.
• Intuitive Surgical reported a quarterly revenue of $2.44 billion, exceeding expectations, and an earnings per share of $2.19, surpassing the consensus estimate of $1.93.

Silver Oak Securities Incorporated decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 47.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,110 shares of the medical equipment provider's stock after selling 987 shares during the quarter. Silver Oak Securities Incorporated's holdings in Intuitive Surgical were worth $603,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ISRG. Chilton Capital Management LLC lifted its position in Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after buying an additional 43 shares in the last quarter. Global Financial Private Client LLC lifted its position in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares in the last quarter. Elite Financial Inc. purchased a new stake in Intuitive Surgical in the first quarter valued at $26,000. LFA Lugano Financial Advisors SA purchased a new stake in Intuitive Surgical in the first quarter valued at $30,000. Finally, TD Capital Management LLC raised its position in Intuitive Surgical by 300.0% in the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 45 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $438.72 on Monday. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The company has a market capitalization of $157.27 billion, a P/E ratio of 61.19, a PEG ratio of 4.60 and a beta of 1.61. The stock has a 50-day simple moving average of $476.64 and a 200-day simple moving average of $503.43.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the business earned $1.78 EPS. The business's quarterly revenue was up 21.4% on a year-over-year basis. As a group, analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Evercore ISI lifted their target price on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. BTIG Research lifted their target price on Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Truist Financial lifted their target price on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Wells Fargo & Company lifted their target price on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday, July 23rd. Finally, Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $595.95.

Insider Activity

In other Intuitive Surgical news, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider directly owned 19,827 shares of the company's stock, valued at $9,368,059.23. This represents a 59.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy L. Ladd sold 335 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $440.69, for a total value of $147,631.15. Following the sale, the director directly owned 739 shares of the company's stock, valued at approximately $325,669.91. This represents a 31.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 45,224 shares of company stock valued at $21,716,492. Insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.